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a b s t r a c t
Inhibitors of mammalian target of rapamycin (mTOR) have immunosuppressive and anti-cancer effects, but
their effects on the progression of kidney disease are not fully understood. Using cells from normal kidney
epithelial cell lines, we found that the antiproliferative effects of mTOR inhibitor everolimus accompanied
the accumulation of a marker for cellular autophagic activity, the phosphatidylethanolamine-conjugated
form of microtubule-associated protein 1 light chain 3 (LC3-II) in cells. We also showed that the primary
autophagy factor UNC-51-like kinase 1 was involved in the antiproliferative effects of everolimus. Levels of
LC3-II decreased in the kidneys of rats treated with ischemia-reperfusion or cisplatin; however, renal LC3-II
levels increased after administration of everolimus to rats subjected to ischemia-reperfusion or cisplatin
treatment. Simultaneously, increased signals for kidney injury molecule-1 and single-stranded DNA and
decreased signals for Ki-67 in the proximal tubules were observed after treatment with everolimus,
indicating that everolimus diminished renal function after acute tubular injury. We also found leakage of
LC3 protein into rat urine after treatment with everolimus, and urinary LC3 protein was successfully
measured between 0.1 and 500 ng/mL by using an enzyme-linked immunosorbent assay. Urinary LC3
levels were increased after administration of everolimus to rats subjected to ischemia-reperfusion or
cisplatin treatment, suggesting that renal LC3-II and urinary LC3 protein are new biomarkers for autophagy
in acute kidney injury. Taken together, our results demonstrated that the induction of autophagy by
everolimus aggravates tubular dysfunction during recovery from kidney injury.
& 2012 Elsevier B.V. All rights reserved.
1. Introduction
Everolimus is as an immunosuppressive macrolide derived
from sirolimus (rapamycin) that inhibits the kinase activity of
mammalian target of rapamycin (mTOR) (Wullschleger et al.,
2006). The renal toxicity of everolimus is thought to be lower
than that of other agents, such as calcineurin inhibitors (e.g.,
cyclosporine or tacrolimus, which are often used as primary
immunosuppressants after organ transplantation) (Lehmkuhl
et al., 2005; Schweiger et al., 2006). However, de novo use of
mTOR inhibitors after renal transplantation has been reported to
cause decreased renal graft survival (Ekberg et al., 2007) and
delayed wound healing (Kahn et al., 2005).
Previous studies in models of progressive kidney disease have
shown that sirolimus and everolimus have preventive effects on
renal hypertrophy and fibrosis (Huber et al., 2011). Recently, we
demonstrated that the mTOR pathway is activated in the proximal
tubular cells of rat kidneys after subtotal nephrectomy (Nakagawa
et al., 2010). We found that treatment with everolimus in rats
8 weeks after subtotal nephrectomy, an animal model of end-stage
renal disease, had restorative effects on the tubular reabsorption
of albumin and the expression levels of membrane transporters in
the proximal tubules. However, mTOR inhibitors also display
adverse effects on the kidneys. Treatment with mTOR inhibitors
in ischemia-reperfusion injury deteriorates the renal function of
rats and mice by preventing recovery (Esposito et al., 2011;
Lieberthal et al., 2001). In addition, we found that everolimus
treatment in rats 2 weeks after subtotal nephrectomy, an animal
model of compensative chronic renal failure, prevented cellular
hyperplasia of the proximal tubules, resulting in severe renal
damage (Nishihara et al., 2010). These findings suggest that mTOR
inhibitors could contribute to renal toxicity by inhibiting the
adaptive response of tubular cells during acute kidney injury,
and therefore, biomarkers are needed to predict treatment out-
comes with mTOR inhibitors during kidney injury.
The mTOR pathway is known to regulate autophagy
(Wullschleger et al., 2006). Recent studies have shown that the
active mTOR pathway suppresses autophagy by preventing UNC-
51-like kinase 1 (Ulk1) activity (Chan et al., 2007). Autophagy is
an evolutionarily conserved process through which organelles or
long-lived proteins are sequestered in a double-membrane vesicle
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‘‘autophagosome’’ and subsequently degraded in lysosomes
(Levine and Kroemer, 2008). Because the cytosolic form of
microtubule-associated protein 1 light chain 3 (LC3-I) is modified
into its phosphatidylethanolamine-conjugated form, LC3-II,
which is associated with autophagosomes, LC3-II has been exam-
ined as a marker for autophagic activity (Mizushima et al., 2010).
Recent studies have focused on the roles of autophagy in kidney
disease; however, the influence of mTOR activation on the LC3-II
levels in the kidneys remains to be delineated.
Given these findings, we examined the association between
the mTOR pathway and autophagy in the kidney. Our results
demonstrated that mTOR inhibition with everolimus induced the
renal accumulation of LC3-II in acute kidney injury, preventing
tubular cell proliferation after injury. We also identified the
presence of LC3 protein in rat urine and found that the quanti-
fication of urinary LC3 was beneficial in the evaluation of the
pharmacological activity of mTOR inhibitors in the kidney.
2. Materials and methods
2.1. Animals
Wistar/ST rats were purchased from SLC Animal Research
Laboratories (Shizuoka, Japan) and cared for in accordance with
Fig. 1. Experimental designs. (A) Kidneys were collected 1, 2, 4, and 7 days after
treatment to examine the effects of ischemia-reperfusion or cisplatin alone. (B)
Rats were administered everolimus (2 mg/kg body weight per day) or vehicle
subcutaneously for 7 days to examine effects of everolimus. On the fifth day, the
rats were subjected to ischemia-reperfusion or treated with cisplatin. Black
arrowheads, treatment with ischemia-reperfusion or cisplatin; white arrowhead,
initiation of administration of everolimus; arrows, sample collection; gray bar,
administration of everolimus.
Fig. 2. Localization of Ulk1 and LC3 in rat kidneys. Normal rat kidney sections were stained with Alexa 488-phalloidin, an antibody against UNC-51-like kinase 1 (Ulk1) or
microtubule-associated protein 1 light chain 3 (LC3). Red signals for Ulk1 (E), (H) or LC3 (K) were merged with green signals for phalloidin (D), (G) and (J) in the same
section (F), (I) and (L). Magnification, 200 (A)–(C) and 400 (D)–(L); scale bars, 100 mm (A)–(C) and 50 mm (D)–(L). OSOM, outer stripe of outer medulla; ISOM, inner
stripe of outer medulla. (*), glomeruli.
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the Guidelines for Animal Experiments of Kyoto University.
All protocols were approved by the Animal Research Committee,
Graduate School of Medicine, Kyoto University. For studies on the
effects of starvation, 8-week-old rats were deprived of food
for 0 or 48 h. These rats had free access to drinking water.
To investigate the effects of ischemia-reperfusion, we subjected
8-weeks-old rats to ischemia-reperfusion following a protocol
published elsewhere (Gonc-alves et al., 2006). In brief, both renal
pedicles were cross-clamped for 40 min. During the procedure,
animals were well hydrated with saline and maintained at a
constant temperature (37 1C) using a heating pad. Sham-operated
rats at 2 days after surgery were used as controls. To induce
nephrotoxicity with cisplatin, we intraperitoneally administered
cisplatin (5 mg/kg; Randas; Nippon Kayaku Co., Ltd., Tokyo,
Japan) to 8-week-old rats. Control rats were administered the
same volume of saline. Kidneys were collected 1, 2, 4, and 7 days
after ischemia-reperfusion or cisplatin treatment (Fig. 1A). The
levels of blood urea nitrogen and plasma creatinine (PCr) were
measured to examine renal function by using assay kits from
Fig. 3. Pharmacological effects of everolimus in normal kidney epithelial cell lines.(A) Human kidney 2 (HK-2), Madin–Darby canine kidney (MDCK), and normal rat kidney
epithelial (NRK-52E) cells were treated with everolimus (Eþ , 100 nM) or vehicle (E) for 48 h. After treatment, whole-cell extracts were obtained and examined with
Western blotting using antibodies against LC3 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). GAPDH was used as a loading control to determine the relative
densities of the bands in each lane. The ratio of the density of everolimus-treated cells to that of vehicle-treated cells was calculated. Each column represents the
mean7S.E.M. (n¼3; *Po0.05, significantly different). (B) After the cells were exposed to everolimus for 48 h, viable cell number was determined. The viable cell number
of the cells treated with vehicle alone was regarded as 1.0. Each column represents the mean7S.E.M. of 3 wells. *Po0.05, **Po0.01, significantly different. (C) Protein
expression of Ulk1 in NRK-52E cells was examined with Western blotting using an antibody against Ulk1. Cells were transfected with small interfering RNA (siRNA)
targeting rat Ulk1 (siUlk1) or negative-control siRNA (siControl). (D)–(G) After transfection with siControl or siUlk1, cells were treated with vehicle alone or everolimus at
various concentrations. The viability of the control cells at 0 h was regarded as 1.0. Each point represents the mean7S.E.M. (n¼3).
Fig. 4. Examination of LC3-II levels in rat skeletal muscles after starvation. (A)
Whole-tissue homogenates were prepared from skeletal muscles after a 0- or 48-h
starvation and subjected to western blotting using antibodies against LC3 and
GAPDH. (B) The relative densities of the bands in each lane were determined, and
the ratio of the density of the cells of starved rats to that of the cells of control rats
was calculated. GAPDH was used as an internal standard. **Po0.01, significantly
different from control rats.
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Wako Pure Chemical Industries (Osaka, Japan). The urinary
protein concentration was determined using a Bradford protein
assay (Bio-Rad Laboratories, Hercules, CA).
Rats were subcutaneously administered everolimus (2 mg/kg
body weight per day; LC Laboratories, Woburn, MA) or vehicle
(90% saline, 5% ethanol, 5% Cremophors EL [Nacalai Tesque,
Kyoto, Japan]). The rats were administered everolimus for 5 days
to obtain a stable everolimus blood concentration (Fig. 1B). On the
sixth day, the rats were subjected to ischemia-reperfusion or
treated with cisplatin.
2.2. Cell culture
Cells from kidney epithelial cell lines (human kidney 2 [HK-2],
ATCC CRL-2190; Madin–Darby canine kidney [MDCK], ATCC CCL-
34; normal rat kidney epithelial [NRK-52E], ATCC CRL-1571;
American Type Culture Collection, Manassas, VA) were cultured
in complete medium consisting of Dulbecco’s modified Eagle’s
medium (Wako) with 10% fetal bovine serum (Whittaker Biopro-
ducts Inc., St. Louis, MO) in an atmosphere of 5% CO2–95% air at
37 1C. The effects of everolimus on viable cell number and LC3-II
were measured after exposure to everolimus for 48 h.
The effect of everolimus on cell proliferation was determined
by adapting a published previously protocol (Iwamaru et al.,
2007). Cell viability was determined using a WST-8 cell prolifera-
tion reagent kit (Nacalai Tesque) according to the manufacturer’s
instructions. The cells were seeded into 24 wells at 2104 cells
per well and incubated overnight in an atmosphere of 5% CO2–95%
air at 37 1C. After exposure to everolimus (100 nM) for 48 h, the
cells were incubated with cell culture medium containing 10%
WST-8 for 1 h, and the absorbance of the samples against a
background control was measured. The viability of the cells
treated with vehicle alone was set as 1.0. For the RNA interference
system, the sequence of small interfering RNA (siRNA) targeting
rat Ulk1 was as follows: 50-GCUCUCAGAGUUUGCUGACCCUGUU-
30. The siRNA was synthesized by Invitrogen Life Technologies
(Carlsbad, CA). We used Stealths RNAi Negative Control Duplexes
(Invitrogen) as the negative control. On the day before transfec-
tion, the cells were seeded into 48-well plates at a density of
7.5103 cells per well. The cells were transfected with 8 pmol per
well siRNA by using 0.4 mL Lipofectamine RNAi MAXs (Invitrogen)
according to the manufacturer’s instructions. Twenty-four hours
after transfection, the cells were treated with vehicle alone or
everolimus (1–100 nM) for 48 h.
2.3. Western blotting
Cells, rat skeletal muscles and rat whole kidneys were homo-
genized in lysis buffer (50 mM Tris–HCl (pH 7.5), 150 mM NaCl,
10 mM NaF, 1 mM Na4P2O7, 1 mM Na3VO4, 1% NP-40, and 1%
protease inhibitor cocktail). To solubilize LC3-II completely, we
boiled and subsequently separated fresh samples using sodium
dodecyl sulfate polyacrylamide gel electrophoresis and transferred
them to polyvinylidene difluoride membranes (Merck Millipore,
Darmstadt, Germany). Membranes were blocked, washed, and
incubated overnight at 4 1C with primary antibodies to total S6
(Cell Signaling Technology #2317, Tokyo, Japan), phosphorylated
ribosomal protein S6 (p-S6; Cell Signaling Technology #2211), LC3
(Novus Biologicals NB100-2331, Littleton, CO), glyceraldehyde
3-phosphate dehydrogenase (GAPDH; Santa Cruz Biotechnology
sc-59540, Avenue, CA), Ulk1 (Santa Cruz Biotechnology sc-33182),
and phosphorylated Ulk1 (p-Ulk1; Cell Signaling Technology
#6888). The bound antibodies were detected on X-ray film by
using enhanced chemiluminescence with horseradish peroxidase
(HRP)-conjugated secondary antibodies and cyclic diacylhydra-
zides (Merck Millipore). The relative densities of the bands in each
lane were determined using NIH Image J 1.39 (National Institutes
of Health, Bethesda, MD).
For the urine analysis, urine samples collected from the bladders
of the rats were concentrated using ultrafiltration membrane units
(Amicon Ultra 3 kDa, Merck Millipore) and diluted with 20 mM
Tris–HCl. Concentrated urine was separated using sodium dodecyl
sulfate polyacrylamide gel electrophoresis and blotted onto poly-
vinylidene difluoride membranes. Two antibodies specific for LC3
(Novus Biologicals NB100-2331B and Cell Signaling Technology
#2775) were used as primary antibodies.
2.4. Measurement of urinary LC3
Urine was collected from the bladders of the rats and stored at
80 1C until use. Urinary LC3 was measured using a sandwich
enzyme-linked immunosorbent assay (ELISA). One antibody specific
Fig. 5. Effects of ischemia-reperfusion on autophagy in rat kidneys. Rats were
subjected to ischemia-reperfusion. Kidneys were collected 1, 2, 4, and 7 days after
surgery. Rats in the control group were sham-operated, and kidneys were
collected 2 days after surgery. The number of rats in each group was 6. (A)–(E)
Whole-kidney homogenates were subjected to Western blotting. The expression
levels of LC3, total Ulk1, phosphorylated Ulk1 (p-Ulk1), total ribosomal protein S6,
phosphorylated S6 (p-S6), and GAPDH were examined. (B)–(E) The relative
densities of the bands in each lane were determined. (F), (G) Renal function was
assessed by measuring plasma creatinine concentration (PCr) and blood urea
nitrogen levels. Multiple comparisons were performed using Dunnett’s 2-tailed
test. *Po0.05, **Po0.01, significantly different from control rat kidneys.
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for LC3 (Cell Signaling Technology #2775) served as a capture
antibody. Another biotinylated LC3 antibody (Novus Biologicals
NB100-2331B) was used as a detection antibody. The wells of a
96-well plate (ELISA Starter Accessory Kit, Bethyl Laboratories,
Montgomery, TX) were coated with capture antibody (diluted
1:250) and blocked with 1% bovine serum albumin in phosphate-
buffered saline. Standard LC3 protein (abcam ab87823, Cam-
bridge, UK) in serial dilutions (0–500 ng/mL) or urine samples
were then added to the plate in duplicate. All of the dilutions of
LC3 standards, urine samples, antibodies, and HRP-conjugated
streptavidin (R&D Systems, Minneapolis, MN) were performed in
the blocking solution. After the washing, detection antibody and
then HRP-conjugated streptavidin were added. Color was devel-
oped by adding the 3,3,5,5-tetramethylbenzidine substrate
(Bethyl Laboratories), and the reaction was stopped by adding
2 N H2SO4. Absorbance was measured at 450 nm and corrected
for plate artifacts at 570 nm. Urinary LC3 concentration was
calculated based on the standard curve and expressed in ng/mg
creatinine.
2.5. Fluorescence microscopy
After perfusion with 4% paraformaldehyde in phosphate-
buffered saline, the kidneys were embedded in Tissue-Teks
O.C.T. compound (Sakura Finetechnical, Tokyo, Japan) and frozen
rapidly in liquid nitrogen. To detect Ulk1, LC3, kidney injury
molecule-1 (Kim-1), and Ki-67, we cut 5-mm-thick sections of the
rat kidney and covered them with 5% bovine serum albumin
containing 0.3% Triton X-100 at 37 1C for 60 min. The covered
sections were incubated overnight at 4 1C with primary antibo-
dies specific for Ulk1 (Merck Millipore ST1521), LC3 (Novus
Biologicals NB100-2331), Kim-1 (Nakagawa et al., 2010), and Ki-
67 (abcam ab16667), washed 3 times, and incubated with
secondary antibodies (Alexa 546-labeled goat anti-rabbit immu-
noglobulin G [IgG] or Alexa 546-labeled goat anti-mouse IgG; Life
Technologies, Tokyo, Japan), Alexa 488-phalloidin (Life Technolo-
gies) and 40,6-diamidino-2-phenylindole (Wako) at 37 1C for
60 min. As a negative control for Ulk1, primary antibody against
Ulk1 was incubated after preabsorption with recombinant full-
length Ulk1 protein (abcam ab95322). To detect single-stranded
DNA (ssDNA), we treated 5-mm-thick sections with proteinase K
and heated them in 50% formamide. The sections were then
covered with 3% non-fat dry milk at 37 1C for 20 min. The covered
sections were incubated for 30 min at room temperature with a
primary antibody specific for ssDNA (Merck Millipore MAB3299),
washed 3 times, and incubated with secondary antibodies at
room temperature for 30 min. Images for immunofluorescent
analysis were captured and examined with a BZ-9000 (Keyence,
Osaka, Japan). To evaluate the levels of LC3, Kim-1, Ki-67, and
ssDNA, we took 20 independent photographs of the renal cortex
(at 1000magnification for LC3; at 100magnification for Kim-
1, Ki-67, and ssDNA) and counted the dot structures in the
proximal tubules (for LC3), the stained proximal tubules (for
Kim-1), or nuclei (for Ki-67 and ssDNA).
Fig. 6. Effects of everolimus in rat kidneys after treatment with ischemia-reperfusion. Rats were administered everolimus (Eþ , 2 mg/kg per day) or vehicle (E) for 7 days.
On day 5 of administration, rats were also subjected to ischemia-reperfusion. Kidneys were collected on day 2 post-treatment. In a control group, rats were sham-operated,
and kidneys were collected on day 2 after surgery. The expression levels of LC3, total Ulk1, p-Ulk1, total S6, p-S6, and GAPDH were examined using Western blot analysis
(A). The relative densities of the bands in each lane were determined (B)–(D). *Po0.05, **Po0.01, yPo0.05, yyPo0.01 show significant difference.
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2.6. Statistical analysis
Data are expressed as mean7S.E.M. Data were statistically
analyzed using the unpaired t test or multiple comparisons after
one-way analysis of variance. Probability values of less than 0.05
were considered statistically significant. Statistical analysis was
performed using Prism Version 4.0 software (GraphPad, San
Diego, CA).
3. Results
3.1. Localization of Ulk1 in rat kidneys
First, renal localization of Ulk1 was examined using immuno-
fluorescent analysis (Fig. 2). Signals for Ulk1 were predominantly
observed in the cortex (Fig. 2A–C). The serial sections were stained
with phalloidin and antibodies against Ulk1. Phalloidin conjugated
with F-actin, making signals for phalloidin abundant at glomeruli
and the luminal side of proximal tubules (Fig. 2D and G). The results
showed that the intensities of the signals for Ulk1 were relatively
higher in proximal tubular epithelial cells (Fig. 2D–F). The preab-
sorption of antibody with Ulk1 protein abolished these positive
signals (Fig. 2G–I), demonstrating the presence of Ulk1 protein in
proximal tubular epithelial cells. Furthermore, the signals for LC3
were observed in the proximal tubular epithelial cells (Fig. 2J–L).
3.2. Effects of everolimus on renal tubular epithelial cell lines
To characterize the effects of everolimus on tubular epithelial cells,
we carried out in vitro experimentation with the renal tubular
epithelial cell lines HK-2, MDCK, and NRK-52E. LC3-II levels in the
cells were determined using recommended methods in mammalian
autophagy research (Klionsky et al., 2008; Mizushima et al., 2010). In
the renal tubular epithelial cell lines, the LC3-II levels were signifi-
cantly increased in cells exposed to everolimus for 48 h compared
Fig. 7. Effects of everolimus on renal functions after ischemia-reperfusion. Levels of PCr) (A), kidney weight (B), LC3 (C)–(E), kidney injury molecule-1 (Kim-1; (F)–(H)),
single-stranded DNA (ssDNA) (I)–(K), and Ki-67 (L)–(N) were examined after concomitant treatment with everolimus and ischemia-reperfusion. Green signals for
phalloidin are merged with red signals for LC3 (C), (D); Kim-1 (F), (G); ssDNA (I), (J); or Ki-67 (L), (M). Magnification, 400 ; scale bars, 50 mm; (*), glomeruli. The numbers
of dot signals (for LC3, (E)); stained proximal tubules (for Kim-1, (H)); or stained nuclei (for ssDNA, (K); Ki-67, (N)) were counted. Each column represents the
mean7S.E.M. (*Po0.05, **Po0.01, yPo0.05, and yyPo0.01 show significant differences).
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with those treated with vehicle (Fig. 3A). Simultaneously, the treat-
ment of everolimus decreased the number of viable cells (Fig. 3B). To
determine the involvement of Ulk1 in the effect of everolimus on cell
proliferation, we used siRNA-targeting rat Ulk1 (siUlk1). The protein
expression levels of Ulk1 in NRK-52E cells were markedly decreased
after treatment with siUlk1 (Fig. 3C). Transfection with siUlk1
significantly decreased the cell viability at 24, 36, and 48 h after
treatment with vehicle alone (Fig. 3D). While the treatment with
everolimus (1, 10, and 100 nM) markedly inhibited cell proliferation
of control cells, transfection with siUlk1 attenuated the anti-
proliferative effect of everolimus (Fig. 3E–G).
3.3. Effects of ischemia-reperfusion on the mTOR pathway in the
kidney
Before assessing LC3-II levels in vivo, we validated our meth-
ods based on a previous report that the levels of LC3-II in muscle
tissue increases after nutrient starvation (Mizushima et al., 2004).
The levels of LC3-II in rat skeletal muscles after fasting for 0 or
48 h was examined. As shown in Fig. 4, fasting for 48 h signifi-
cantly increased LC3-II levels in muscles.
Next, we examined the effects of ischemia-reperfusion on the
levels of LC3-II, p-Ulk1, and p-S6. ischemia-reperfusion injury was
used as a model of acute tubular necrosis. A reduction in renal
blood flow during ischemia and subsequent reperfusion caused
pronounced tubular necrosis, endothelial injury, and leukocyte
activation (Bonventre and Weinberg, 2003). The levels of LC3-II 1,
2, and 4 days after ischemia-reperfusion were significantly lower
than those in normal rat kidneys (Fig. 5A and B). Recent studies
showed that mTOR phosphorylates Ulk1 at Ser 757. We found
that phosphorylation of Ulk1 in the kidneys increased signifi-
cantly 1, 2, and 4 days after ischemia-reperfusion (Fig. 5A and C).
Levels of p-S6 have been used to distinguish the activation of the
mTOR pathway in mice and rat kidneys. Phosphorylated S6 and
total S6 levels significantly increased the day after administration
(Fig. 5A, D, and E). These results clearly showed that the mTOR
pathway was activated after ischemia-reperfusion. In this model,
the levels of PCr and blood urea nitrogen were significantly
increased 1 and 2 days after ischemia-reperfusion (Fig. 5F and G).
3.4. Effects of everolimus in ischemia-reperfusion injury
We defined the effects of everolimus on the levels of LC3-II,
p-Ulk1, and p-S6 in the kidneys after treatment with ischemia-
reperfusion. Ischemia-reperfusion decreased the levels of LC3-II and,
conversely, increased those of p-Ulk1 and p-S6; however, treatment
with everolimus restored the levels of LC3-II (Fig. 6A and B and
Fig. 7C–E) and decreased the levels of p-Ulk1 and p-S6 (Fig. 6A, C,
and D), indicating that the mTOR pathway was activated after
ischemia-reperfusion regulated LC3-II levels in the kidney.
We also explored the effects of everolimus on renal function. The
PCr levels after ischemia-reperfusion were markedly increased by
pretreatment with everolimus (Fig. 7A). In addition, everolimus
pretreatment prevented renal hypertrophy after ischemia-
reperfusion (Fig. 7B). Kidney sections were stained with antibodies
for Kim-1, a marker for tubular injury (Ichimura et al., 1998; Vaidya
et al., 2010; Yang et al., 2010), ssDNA, a marker for apoptotic cells
(Elliott et al., 2009), and Ki-67, a proliferation marker (Gerdes et al.,
1984). Co-treatment with everolimus and ischemia-reperfusion
markedly increased levels of Kim-1 (Fig. 7F–H) and apoptotic cells,
as indicated by the number of nuclei with ssDNA immunostaining
(Fig. 7I–K). In addition, the results showed that numbers of Ki-67–
positive nuclei were significantly decreased in the everolimus-
treated rats (Fig. 7L–N).
3.5. Effects of cisplatin on the mTOR pathway in the kidney
To clarify the effects of cisplatin on the mTOR pathway in the
kidney, we examined LC3-II and pS6 levels 1, 2, 4, and 7 days after
administration. Cisplatin was used as a typical model of drug-
induced nephrotoxicity; it was taken into renal proximal tubular
cells via membrane transporters (Yonezawa and Inui, 2011) such
that it exerted its cytotoxicity specifically in proximal tubular
cells. The levels of LC3-II were significantly lower in kidneys
treated with cisplatin than in normal rat kidneys (Fig. 8A and B).
In addition, we observed increased phosphorylation of Ulk1 1 and
2 days after administration (Fig. 8A and C). The day after admin-
istration, the levels of p-S6, but not total S6 levels, significantly
increased (Fig. 8A, D, and E). These results clearly showed that the
mTOR pathway was activated 1 day after exposure to cisplatin. PCr
Fig. 8. Effects of cisplatin on autophagy in rat kidneys. Rats were intraperitoneally
administered cisplatin (5 mg/kg body weight). Kidneys were collected 1, 2, 4, and
7 days after administration. As a control group, rats were administered vehicle,
and kidneys were collected 2 days after administration. The number of rats in each
group was 6. (A)–(E) Whole-kidney homogenates were subjected to Western
blotting. The expression levels of LC3, total Ulk1, p-Ulk1, total S6, p-S6, and
GAPDH were examined. (B)–(E) The relative densities of the bands in each lane
were determined. (F), (G) Renal function was assessed by measuring PCr and blood
urea nitrogen levels. Multiple comparisons were performed using Dunnett’s
2-tailed test. *Po0.05, **Po0.01, significantly different from control rat kidneys.
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and blood urea nitrogen levels significantly increased 4 days after
administration (Fig. 8F and G).
3.6. Effects of everolimus in cisplatin-induced nephropathy
Next, we examined the effects of everolimus on the levels of
LC3-II, p-Ulk1, and p-S6 in the kidney after treatment with
cisplatin. Exposure to cisplatin markedly decreased the levels of
LC3-II and increased the levels of p-Ulk1 and p-S6 in the kidneys;
however, everolimus treatment resulted in the accumulation
of LC3-II (Fig. 9A and B and Fig. 10C–E) and dephosphorylation
of Ulk1 and S6 (Fig. 9A, C and D), which indicated that the mTOR
pathway regulated the levels of LC3-II in the kidney after cisplatin
treatment.
After co-treatment with everolimus and cisplatin, the PCr
levels were significantly higher than those in control rats
(Fig. 10A), suggesting that mTOR inhibition with everolimus
worsened renal function. Furthermore, kidney weight tended to
be altered by everolimus treatment (Fig. 10B). We also explored
the effects of everolimus on the levels of Kim-1 and apoptosis.
Although not statistically significant, the number of proximal
tubules with Kim-1 immunostaining nearly doubled after co-
treatment with everolimus and cisplatin (Fig. 10F–H). Conversely,
the number of apoptotic cells was comparable in the treatment
and control groups (Fig. 10I–K). However, everolimus treatment
significantly decreased the number of Ki-67–positive nuclei in
tubular epithelial cells (Fig. 10L–N).
3.7. Quantification of urinary LC3
We next examined whether LC3 protein was present in rat
urine. After co-treatment with everolimus and cisplatin, LC3-I and
LC3-II were detected in the urine (Fig. 11A). In addition, we
confirmed that two antibodies produced using different epitopes
of LC3 could detect both LC3-I and LC3-II in the urine. To quantify
the concentration of LC3 in rat urine after everolimus treatment,
an LC3 sandwich ELISA was constructed using these two anti-
bodies. A standard curve was generated with serial dilutions of a
synthetic peptide of LC3 starting with 500 ng/mL (Fig. 11B). The
lower limit of detection – defined as the lowest LC3 peptide
concentration that was significantly differentiated from 0 (assay
blank) by an unpaired t test (n¼3, Po0.001) – was 0.122 ng/mL.
The coefficient of variation obtained for each standard from 0.122
to 500 ng/mL waso10%.
Next, urinary LC3 concentration was measured in rats taken
from the ischemia-reperfusion and cisplatin groups described
above. The mean urinary LC3 concentration in the everolimus-
treated group was significantly higher than that in the vehicle-
treated group (Fig. 11C and D).
4. Discussion
Recent findings have demonstrated that mTOR inhibitors have
therapeutic effects in progressive kidney diseases, including poly-
cystic kidney disease and diabetic nephropathy (Huber et al., 2011),
Fig. 9. Effects of everolimus in rat kidneys after treatment with cisplatin. Rats were administered everolimus (Eþ , 2 mg/kg per day) or vehicle (E) for 7 days. On day 5 of
administration, rats were also administered cisplatin. Kidneys were collected on day 2 post-treatment. As a control group, rats were administered the vehicle, and kidneys
were collected on day 2 after administration. The expression levels of LC3, total Ulk1, p-Ulk1, total S6, p-S6, and GAPDH were examined using Western blot analysis (A).
The relative densities of the bands in each lane were determined (B)–(D). *Po0.05, yPo0.05 show significant difference.
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but mTOR inhibitors can also cause renal toxicity (Lieberthal et al.,
2001; Nishihara et al., 2010). Therefore, the details of the action of
mTOR inhibitors in the kidney need to be clarified to aid the
development of targeted therapy against kidney disease.
Ulk1 has been shown to be necessary for the induction of
autophagy by mTOR inhibitors (Chan et al., 2007); however, the
roles of Ulk1 in the antiproliferative effects of everolimus remain
unclear. Immunofluorescence analysis showed expression of Ulk1
and LC3 proteins in the proximal tubular epithelial cells of rat
kidneys (Fig. 2). The results suggested that the mTOR-Ulk1 path-
way had active roles in the proximal tubular epithelial cells. They
also indicated that the monitoring of LC3-II levels in the kidney
was useful for evaluating mTOR activity and the efficacy of mTOR
inhibition with everolimus in proximal tubular cells. We found
that the accumulation of LC3-II resulting from everolimus treat-
ment accompanied the prevention of cell proliferation in renal
tubular epithelial cell lines (Fig. 3A and B). Notably, treatment
with siUlk1 reduced the antiproliferative effects of everolimus in
NRK-52E cells (Fig. 3D–G). These results showed that Ulk1 and its
downstream cellular events, such as autophagy, had key roles in
the antiproliferative effects of everolimus.
After ischemia-reperfusion injury, renal tubular epithelial cells
rapidly enter the cell cycle to adapt to the loss of neighboring cells
by proliferating and replacing the dead cells (Venkatachalam et al.,
1978). Previous studies in mouse and rat kidneys have suggested
that the mTOR pathway is involved in the repair of renal tubular
cells after acute injury (Gonc-alves et al., 2006; Lieberthal et al.,
2001). To characterize roles of the mTOR pathway after ischemia-
reperfusion injury, we examined influences of mTOR activation on
autophagy in ischemia-reperfusion injury. We found that the levels
of LC3-II in the kidneys decreased when the mTOR pathway was
activated (Fig. 5). In contrast, co-treatment with everolimus and
ischemia-reperfusion resulted in the accumulation of renal LC3-II
(Fig. 6). These results suggested that the activated mTOR pathway
after ischemia-reperfusion was involved in decreasing LC3-II levels
in the kidney. We also found that Kim-1 levels and the number of
apoptotic cells in the renal cortex increased after everolimus
treatment (Fig. 7). The results from tubular cell lines (Fig. 3)
Fig. 10. Effects of everolimus on renal functions after cisplatin treatment. Levels of PCr (A), kidney weight (B), LC3 (C)–(E), Kim-1 (F)–(H), single-stranded DNA (ssDNA) (I)–
(K), and Ki-67 (L)–(N) were examined after concomitant treatment with everolimus and cisplatin. Green signals for phalloidin are merged with red signals for LC3 (C), (D),
Kim-1 (F), (G), ssDNA (I), (J), or Ki-67 (L), (M). Magnification, 400 ; scale bars, 50 mm; (*), glomeruli. The numbers of dot signals (for LC3, (E)), stained proximal tubules (for
Kim-1, (H)), or stained nuclei (for ssDNA, (K); Ki-67, (N)) were counted. Each column represents the mean7S.E.M. (*Po0.05 and **Po0.01 show significant differences).
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suggested that mTOR inhibition prevented cell proliferation in the
proximal tubules after ischemia-reperfusion by inducing LC3-II
accumulation. These results suggest that the proximal tubular cells
underwent autophagy-mediated cell death after treatment with
everolimus and ischemia-reperfusion. Shimizu et al. demonstrated
autophagy-dependent programmed cell death in embryonic fibro-
blasts from Bax/Bak double-knockout mice (Shimizu et al., 2004).
Furthermore, it was reported that cytotoxicity of temozolomide and
sirolimus against human malignant glioma cells was caused by
induction of autophagy (Iwamaru et al., 2007; Kanzawa et al., 2004).
These findings suggest that the use of mTOR inhibitors in acute
kidney injury could mediate cellular demise of proximal tubules via
the direct self-destructive potential of excessive autophagy.
After exposure to cisplatin, the activation of cell survival path-
ways, including those of phosphoinositide-3 kinase and Akt/protein
kinase B, in proximal tubules was observed (Kuwana et al., 2008).
Inhibition of these pathways caused severe tubular injury, indicating
compensative roles of these pathways in the maintenance of renal
function. In this study, we found mTOR pathway activation after
cisplatin administration (Fig. 8) and noted that everolimus pretreat-
ment diminished renal function and prevented cell proliferation in
proximal tubules (Fig. 10). These results indicated that the active
mTOR pathway in proximal tubular epithelial cells after cisplatin
administration served as a cell survival pathway. Therefore, co-
treatment of everolimus and cisplatin in cancer therapy could cause
severe renal dysfunction by preventing the cell survival functions of
proximal tubular cells.
Recent studies have shown that mTOR and AMP-activated protein
kinase (AMPK) are the most important regulators of Ulk1-mediated
autophagy (Egan et al., 2011; Kim et al., 2011). mTOR inhibits the
phosphorylation-mediated activation of Ulk1 at Ser 757 and disrupts
the interaction between Ulk1 and AMPK. We found significant
increase in Ulk1 phosphorylation (Ser 757) in the rat kidneys after
ischemia-reperfusion injury and treatment with cisplatin (Figs. 5, 6, 8,
and 9): however, we found a decrease in the total protein expression
levels of Ulk1 in the kidneys after acute injury. Although further
studies are required to have a comprehensive understanding of Ulk1
regulation in the kidney, and our results showed direct interaction
between mTOR and Ulk1 in the kidney.
Interestingly, ischemia-reperfusion treatment induced signifi-
cant increase in the total levels of S6 in the kidneys (Fig. 5), but
cisplatin treatment did not (Fig. 8). Ribosomal protein S6 plays
important roles in cell growth and proliferation (Ruvinsky and
Meyuhas, 2006). Previous studies showed that the expression
level of S6 protein increased in serum-stimulated cells (Tushinski
and Warner, 1982). In this study, a higher number of tubular
epithelial cells underwent the cell cycle progression after
ischemia-reperfusion (Fig. 7) than after cisplatin treatment
(Fig. 10). Therefore, not only the phosphorylation status but also
the expression levels of total S6 protein may be the key factors in
the progression of tubular cell proliferation.
The profiles of renal LC3-II levels suggested that autophagic
activity in the kidneys was suppressed during the recovery phase
of ischemia-reperfusion injury and cisplatin-induced nephropathy
Fig. 11. Urinary LC3 concentration after treatment with everolimus. (A) Western blotting of LC3 protein in rat urine using urine collected from rats after co-treatment with
everolimus and cisplatin. Proteins were probed with 2 anti-LC3 antibodies (Detection, the detection antibody in ELISA; Capture, the capture antibody in ELISA). Two bands
(arrowheads) were observed with both antibodies. (B) A typical standard curve using recombinant LC2 protein was made using serial dilutions from a 500 ng/mL
concentration. R2¼0.98 represents a high correlation coefficient. Each point represents the absorbance at 450 nm minus the value of assay blank and is expressed as the
mean7S.E.M. of 3 wells. (C), (D) Rats were administered everolimus (2 mg/kg) or vehicle subcutaneously for 7 days. On the fifth day, the rats were subjected to ischemia-
reperfusion (C) or treated with cisplatin (D). Urinary LC3 concentration (nanograms per milligram creatinine) in each rat was determined (n¼6, each). *Po0.05,
significantly different from vehicle treated rats.
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at least 1 day after treatment (Figs. 5, 8). Furthermore, mTOR
inhibition with everolimus restored the autophagic activity in rat
kidneys subjected to ischemia-reperfusion or cisplatin adminis-
tration (Figs. 6, 9). Accordingly, autophagy in tubular epithelial
cells could be suppressed through the activation of the mTOR
pathway during the recovery phase of acute kidney injury. Con-
versely, a recent study in mice without the Atg5 gene in proximal
tubular cells showed that constitutive suppression of autophagy
resulted in severe tubular dysfunction after ischemia-reperfusion
(Kimura et al., 2011). The results indicated that autophagy has
protective roles against ischemia-reperfusion injury. In rat liver,
activation of autophagy has been observed within 15 min after
ischemia-reperfusion treatment (Gotoh et al., 2009). Taken
together, these results suggest that autophagy in renal tubular
epithelial cells occurs in response to ischemia-reperfusion-
induced hypoxia immediately after ischemia-reperfusion treat-
ment, but autophagy is suppressed through the activation of the
mTOR pathway during the regeneration phase of tubular injury.
Urinary proteins have been found to be sensitive biomarkers of
drug-induced nephropathy, with dose-dependent increases in urinary
concentration correlated to the degree of tissue damage (Ferguson
et al., 2008). Our results indicated that the effects of everolimus on
protein synthesis, autophagy, and cell proliferation in the kidneys,
especially in proximal tubular cells, were detected by the accumula-
tion of LC3-II (Figs. 5, 6, 8, and 9). These findings encouraged us to
assess the availability of urinary LC3 as a non-invasive marker. Using
the ELISA for LC3, we detected LC3 protein in rat urine. We also found
that everolimus pretreatment markedly increased the urinary LC3
levels in rats with ischemia-reperfusion injury and cisplatin-induced
nephropathy (Fig. 11C and D). Although further investigation of the
underlyingmechanisms of this effect is required, these results suggest
that urinary LC3 could be a biological marker for mTOR inhibition
during acute kidney injury.
The present results, which reveal the molecular events underlying
everolimus activity in the kidney, advance knowledge about the roles
of the mTOR pathway in the pathophysiology of acute kidney injury.
The hypothesized molecular mechanisms of mTOR-mediated autop-
hagy in proximal tubular epithelial cells are summarized in Fig. 12.
After exposure to ischemia-reperfusion or nephrotoxicants, the mTOR
pathway in the proximal tubular epithelial cells became active to
promote tubular cell regeneration and suppress autophagy (Fig. 12A).
Activation of the mTOR pathway in the proximal tubules inhibited
the phosphorylation of Ulk1, which possibly disrupted the interaction
between activated p-Ulk1 and AMPK. The use of everolimus resulted
in the accumulation of LC3-II in the cells, however (Fig. 12B). Similar
to the findings shown by Kim et al. that rapamycin treatment in
HEK293 cells inhibited the phosphorylation of Ulk1 but did not
activate AMPK (Kim et al., 2011), our findings showed that ever-
olimus treatment activated Ulk1 by its phosphorylation in the
proximal tubules in an AMPK-independent manner. However, the
precise role of AMPK in Ulk1 activation should be addressed in future
studies. Although the origin of the excretion of LC3-II or LC3-I from
epithelial cells into urine was unclear (i.e., from living cells or from
dead cells), our results showed that the presence of LC3 in urine could
indicate renal tubular injury through mTOR inhibition with ever-
olimus in response to acute proximal tubular damage such as
cisplatin treatment. These results suggest the usefulness of additional
studies to determine the clinical significance of LC3 as a urinary
biomarker in pharmacotherapy with mTOR inhibitors.
In conclusion, we have discovered a novel role for the mTOR
pathway in proximal tubular cells: the regulation of autophagy. Our
data suggested that the use of mTOR inhibitors in acute kidney injury
activates Ulk1 and autophagy, eventually impairing tubular regenera-
tion after acute injury. These findings provide important information
for the development of appropriate protocols for the clinical applica-
tion of mTOR inhibitors.
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